Affiliation:
1. Department of Pediatric Cardiology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China
2. Department of Pediatric Cardiology, the Second Affiliated Hospital&Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325000, China
Abstract
Chronic Heart Failure (CHF) is a complex clinical syndrome with a high incidence worldwide.
Although various types of pharmacological and device therapies are available for CHF, the prognosis
is not ideal, for which, the control of increased Heart Rate (HR) is critical. Recently, a bradycardic
agent, ivabradine, is found to reduce HR by inhibiting the funny current (If). The underlying mechanism
states that ivabradine can enter the Hyperpolarization-activated Cyclic Nucleotide-gated (HCN) channels
and bind to the intracellular side, subsequently inhibiting the If. This phenomenon can prolong the
slow spontaneous phase in the diastolic depolarization, and thus, reduce HR. The clinical trials demonstrated
the significant effects of the drug on reducing HR and improving the symptoms of CHF with
fewer adverse effects. This review primarily introduces the chemical features and pharmacological characteristics
of ivabradine and the mechanism of treating CHF. Also, some expected therapeutic effects on
different diseases were also concluded. However, ivabradine, as a typical If channel inhibitor, necessitates
additional research to verify its pharmacological functions.
Funder
Natural Science Foundation of Shanghai of China
National Natural Science Foundation of China
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,General Medicine
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献